The impact of higher standards in patent protection for pharmaceutical industries under the TRIPS agreement - A comparative study of China and India

World Economy

Volumn 31, Issue 10, 2008, Pages 1367-1382

  Li, Xuan ^a  

^a South Centre   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPARATIVE STUDY; CONFERENCE PROCEEDING; INTELLECTUAL PROPERTY RIGHTS; PHARMACEUTICAL INDUSTRY; TRADE AGREEMENT; TRADE RELATIONS;

ASIA; CHINA; EURASIA; FAR EAST; INDIA; SOUTH ASIA;

EID: 53249084129     PISSN: 03785920     EISSN: 14679701     Source Type: Journal    
DOI: 10.1111/j.1467-9701.2008.01133.x     Document Type: Conference Paper

References (32)

1. Aoki, R., K. Kensuke and H. Yamane (2006), 'Indian Patent Policy and Public Health: Implications from the Japanese Experience', Institute of Developing Economics, Discussion Paper No. 57.
2. Basheer, S. (2005), 'Block Me Not: Are Patented Genes Essential Facilities?', Bepress Legal Series, Working Paper No. 577.
3. Boldrin, M. and D. K. Levine (2008), 'The Pharmaceutical Industry', in M. Boldrin and D. K. Levine, Against Intellectual Monopoly (Cambridge: Cambridge University Press), 212-42.
4. Chaturvedi, K. and J. Chataway (2006), 'Innovation in the Post-TRIPs Regime in Indian Pharmaceutical Firms: Implications for Pharmaceutical Innovation Model', paper presented at Globelics India 2006, 4-7 October.
5. Chaudhuri, S. and P. K. Goldberg (2003), 'The Effects of Extending Intellectual Property Rights Protection to Developing Countries: A Case Study of the Indian Pharmaceutical Market', NBER Working Paper No. 10159 (Cambridge, MA: NBER).
6. Chin, J. C. and G. M. Grossman (1988), 'Intellectual Property Rights and North-South Trade', NBER Working Paper Series No. 2769 (Cambridge, MA: National Bureau of Economic Research).
7. Chin, J. and G. Grossman (1990), 'Intellectual Property Rights and North-South Trade', in R. W. Jones and A. O. Krueger (eds.), The Political Economy of International Trade: Essays in Honor of Robert E. Baldwin (Cambridge, MA: Basil Blackwell), 90-107.
8. Correa, C. M. (2000), International Property Rights, the WTO and Developing Countries. The TRIPS Agreement and Policy Options (London: Zed Books, Third World Network).
9. Deardorff, A. (1992), 'Welfare Effects of Global Patent Protection', Economica, 59, 35-51.
10. Diwan, I. and D. Rodrik (1991), 'Patents, Appropriate Technology, and North-South Trade', Journal of International Economics, 63, 79-90.
11. Federation of Indian Chambers of Commerce and Industry (2005), 'Competitiveness of the Indian Pharmaceutical Industry in the New Product Patent Regime', FICCI Report for National Manufacturing Competitiveness Council.
12. Fink, C. (2000), 'How Stronger Patent Protection in India Might Affect the Behavior of Transnational Pharmaceutical Industries', Working Paper No. 2352 (Washington, DC: World Bank).
13. Frischtak, C. (1989), 'The Protection of Intellectual Property Rights and Industrial Technology Development in Brazil', The World Bank Industry and Energy Department Working Paper, Industry Series Paper No. 13 (Washington, DC: World Bank).
14. FTC (2003), 'To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy', report by the Federal Trade Commission.
15. Gilbert, R. and C. Shapiro (1990), 'Optimal Patent Length and Breadth', RAND Journal of Economics, 21, 106-12.
16. Hasper, M. (2005), 'Intellectual Property Rights Protections in Developing Countries: The Effect of TRIPS on the Production and Dissemination of Cures Specific to Developing Country Diseases', Stanford University, Department of Economics.
17. Helpman, E. (1993), 'Innovation, Imitation, and Intellectual Property Rights', Econometrica, 61, 1247-80.
18. Kamien, M. I. and N. L. Schwartz (1974), 'Patent Life and R&D Rivalry', American Economic Review, 64, 183-87.
19. Klemperer, P. (1990), 'How Broad Should the Scope of Patent Protection Be?', RAND Journal of Economics, 21, 113-30.
20. Lanjouw, J. O. (1998), 'The Introduction of Pharmaceutical Product Patents in India: Heartless Exploitation of the Poor and Suffering?', NBER Working Paper No. 6366 (Cambridge, MA: NBER).
21. Levin, R. C., A. K. Klevorick, R. R. Nelson and S. G. Winter (1987), 'Appropriating the Returns from Industrial Research and Development', Brookings Papers on Economic Activity, No. 3.
22. Management Sciences for Health (2003), International Drug Price Indicator Guide (Cambridge, MA: MSH).
23. Maskus, K. and D. E. Konan (1994), 'Trade-related Intellectual Property Rights: Issues and Exploratory Results', in A. Deardorff and R. M. Stern (eds.), Analytical and Negotiating Issues in the Global Trading System (Ann Arbor, MI: University of Michigan Press), 401-46.
24. Nogués, J. J. (1993), 'Social Costs and Benefits of Introducing Patent Protection for Pharmaceutical Drugs in Developing Countries', The Developing Economies, XXXI, 1, 25-39.
25. Ramani, S. (2002), 'Who is Interested in Biotech? R&D Strategies, Knowledge Base and Market Sales of Indian Biopharmaceutical Firms', Research Policy, 31, 3, 381-98.
26. Rang, H. P. (2006), Drug Discovery and Development -Technology in Transition (Oxford: Churchill Livingstone Elsevier).
27. Segerstrom, P. S., T. C. A. Anant and E. Dinopoulos (1990), 'A Schumpeterian Model of the Product Life Cycle', American Economic Review, 80, 5, 1077-91.
28. Subramanian, A. (1995), 'Putting Some Numbers on the TRIPs Pharmaceutical Debate', International Journal of Technology Management, 10, 151-68.
29. Sun, Q. (2004), 'A Survey of Medicine Prices, Availability, Affordability and Price Components in Shandong Province, China', Center for Health Management and Policy, Shandong University, China.
30. The Centre for Management of IP in Health R&D (2005), 'Innovation in Developing Countries to Meet Health Needs Experiences of Brazil, China, India and South Africa', an overview report to the Commission on Intellectual Property Rights, Innovation and Public Health, CIPIH.
31. WHO and Health Action International (2006), Price, Availability, Affordability: An International Comparison of Chronic Disease Medicines (Cairo: WHO).
32. Zuniga, M. P. and E. Combe (2002), 'Introducing Patent Protection in the Pharmaceutical Section: A First Evaluation on the Mexican Case', Development, 16, 191-221.